Abstract
Hepatitis C virus (HCV) remains a public health problem of global importance, even in the era of potent directly-acting antiviral drugs. In this chapter, I discuss immune responses to acute and chronic HCV infection. The outcome of HCV infection is influenced by viral strategies that limit or delay the initiation of innate antiviral responses. This delay may enable HCV to establish widespread infection long before the host mounts effective T and B cell responses. HCV’s genetic agility, resulting from its high rate of replication and its error prone replication mechanism, enables it to evade immune recognition. Adaptive immune responses fail to keep up with changing viral epitopes. Neutralizing antibody epitopes may be hidden by decoy structures, glycans, and lipoproteins. T cell responses fail due to changing epitope sequences and due to exhaustion, a phenomenon that may have evolved to limit immune-mediated pathology. Despite these difficulties, innate and adaptive immune mechanisms do impact HCV replication. Immune-mediated clearance of infection is possible, occurring in 20-50% of people who contract the disease. New developments raise hopes for effective immunological interventions to prevent or treat HCV infection.
Keywords: Hepatitis C virus, immune response, innate immunity, T cell exhaustion, interferon lambda, neutralizing antibodies.
Current Drug Targets
Title:Innate and Adaptive Immune Responses in Chronic HCV Infection
Volume: 18 Issue: 7
Author(s): Lynn B. Dustin*
Affiliation:
- University of Oxford, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, Kennedy Institute of Rheumatology, Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY,United Kingdom
Keywords: Hepatitis C virus, immune response, innate immunity, T cell exhaustion, interferon lambda, neutralizing antibodies.
Abstract: Hepatitis C virus (HCV) remains a public health problem of global importance, even in the era of potent directly-acting antiviral drugs. In this chapter, I discuss immune responses to acute and chronic HCV infection. The outcome of HCV infection is influenced by viral strategies that limit or delay the initiation of innate antiviral responses. This delay may enable HCV to establish widespread infection long before the host mounts effective T and B cell responses. HCV’s genetic agility, resulting from its high rate of replication and its error prone replication mechanism, enables it to evade immune recognition. Adaptive immune responses fail to keep up with changing viral epitopes. Neutralizing antibody epitopes may be hidden by decoy structures, glycans, and lipoproteins. T cell responses fail due to changing epitope sequences and due to exhaustion, a phenomenon that may have evolved to limit immune-mediated pathology. Despite these difficulties, innate and adaptive immune mechanisms do impact HCV replication. Immune-mediated clearance of infection is possible, occurring in 20-50% of people who contract the disease. New developments raise hopes for effective immunological interventions to prevent or treat HCV infection.
Export Options
About this article
Cite this article as:
Dustin B. Lynn*, Innate and Adaptive Immune Responses in Chronic HCV Infection, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450116666150825110532
DOI https://dx.doi.org/10.2174/1389450116666150825110532 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroinflammation in Sepsis: Sepsis Associated Delirium
Cardiovascular & Hematological Disorders-Drug Targets Management of Connective Tissue Interstitial Lung Disease
Current Respiratory Medicine Reviews Evaluation of Serum Calprotectin Level and Disease Activity in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews Effectiveness of Long-Term Macrolide Therapy in Cryptogenic Organising Pneumonia
Current Respiratory Medicine Reviews Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome
Current Respiratory Medicine Reviews Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry A Study of the Relaxed Mechanisms Induced by Novokinin in the Isolated Porcine Coronary Artery Ring Segments
Protein & Peptide Letters Assessments of Immunomodulatory and Inflammatory effects against Induction of Entamoeba histolytica (HM1 IMS strain) crude extract Antigen in Complete Freund’s Adjuvant Induced Rheumatoid Arthritis Female Wistar Rats
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antileukotriene Drugs: Clinical Application, Effectiveness and Safety
Current Medicinal Chemistry Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Henoch-Schönlein Purpura in Children: An Updated Review
Current Pediatric Reviews Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Granulocyte Colony-Stimulating Factor Attenuates Blood-Brain Barrier Damage and Improves Cognitive Function in Spontaneously Hypertensive Rats
CNS & Neurological Disorders - Drug Targets An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inflammation and Chronic Oxidative Stress in Radiation-Induced Late Normal Tissue Injury: Therapeutic Implications
Current Medicinal Chemistry Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Current Neuropharmacology Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design TAP-Independent MHC Class I Presentation
Current Immunology Reviews (Discontinued)